Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho, J.D., Lee, M.R., Rauch, C.T., Aznavour, K., Park, J.S., Luz, J.G., Antonysamy, S., Condon, B., Maletic, M., Zhang, A., Hickey, M.J., Hughes, N.E., Chandrasekhar, S., Sloan, A.V., Gooding, K., Harvey, A., Yu, X.P., Kahl, S.D., Norman, B.H.(2020) Biochim Biophys Acta Gen Subj 1865: 129800-129800
- PubMed: 33246032 
- DOI: https://doi.org/10.1016/j.bbagen.2020.129800
- Primary Citation of Related Structures:  
6VGC, 6VGI, 6VL4 - PubMed Abstract: 
Due to the importance of both prostaglandins (PGs) and leukotrienes (LTs) as pro-inflammatory mediators, and the potential for eicosanoid shunting in the presence of pathway target inhibitors, we have investigated an approach to inhibiting the formation of both PGs and LTs as part of a multi-targeted drug discovery effort.
Organizational Affiliation: 
Lilly Biotechnology Center, San Diego, CA 92121, USA. Electronic address: ho_joseph_d@lilly.com.